Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 17/20 | 0.49 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2123687 | 0.93 | TNF (0.42) | TNFELANEMAPT | |
| SCHEMBL15204090 | 0.87 | MAPT (0.41) | TNFELANEMAPT | |
| SCHEMBL2123430 | 0.83 | TNF (0.50) | TNF | |
| SCHEMBL2616393 | 0.80 | TNF (0.47) | TNF | |
| SCHEMBL402848 | 0.80 | MAPT (0.56) | TNFMAPT | |
| SCHEMBL2133190 | 0.78 | TNF (0.48) | TNF | |
| SCHEMBL2616394 | 0.78 | TNF (0.46) | TNF | |
| SCHEMBL2616389 | 0.78 | TNF (0.46) | TNF | |
| SCHEMBL2122624 | 0.76 | TNF (0.44) | TNF | |
| SCHEMBL2123060 | 0.75 | MGAM (0.46) | TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443115-B1 | Pyrrolo-pyridine derivatives useful to treat diseases connected to S1P1 receptors | GLAXO GROUP LTD (GB) | 2013-08-28 | — | — | EP | disclosed |
| EP-2443115-B1 | Pyrrolo-pyridine derivatives useful to treat diseases connected to S1P1 receptors | GLAXO GROUP LTD (GB) | 2013-08-28 | — | — | EP | disclosed |
| US-20120101123-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101123-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101123-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2443115-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010145201-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010145201-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101123-A1 | COMPOUNDS | CYP11B2, CYP11B1, GPR119 | TNF 1930/4885ELANE 665/4885MAPT 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.